-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
By Kara Nyberg, PhD Posted: June 24, 2020 New findings from the TRACERx lung study underscore the value of using circulating tumor DNA (ctDNA) to predict NSCLC relapse postsurgery based on the detection of minimal residual disease (MRD). Moreover, the results appear sufficiently robust to begin to support use of ctDNA as a biomarker for…
-
PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC
By Kara Nyberg, PhD Posted: June 24, 2020 The phase II PASSION trial sought to explore the potential synergy between immunotherapy and antiangiogenic drug therapy previously observed in preclinical studies. As reported at AACR, the trial showed that combined second-line treatment with camrelizumab, a PD-1 inhibitor, and apatinib, a VEGFR2 inhibitor, demonstrated promising antitumor activity…
-
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy
By Kara Nyberg, PhD Posted: June 24, 2020 Pneumonitis is a well-known complication associated with immune checkpoint inhibitors (ICI). A collaborative effort between the U.S. Food and Drug Administration (FDA) and Synapse, a consultancy firm, retrospectively analyzed both clinical trial data and real-world data (RWD) taken from the Advocate Aurora Health System to elucidate risk…
-
Single-Agent Pembrolizumab Active Against STK11- and KEAP1- Mutated NSCLC According to KEYNOTE-042 Analysis
By Kara Nyberg, PhD Posted: June 24, 2020 Genomic alterations in STK11 and KEAP1 represent two of the most common and potent contributors to a cold tumor immune microenvironment in nonsquamous NSCLC. Although prior research has shown that these mutations are tied to poor outcomes in patients treated with immune checkpoint blockade, particularly in the…
-
TERAVOLT: Global Registry Investigates Outcomes Among Patients With Thoracic Cancer and COVID-19
By Marina Chiara Garassino, MD, and Leora Horn, MD, MSc, FRCPC Posted: June 9, 2020 Marina Chiara Garassino Leora Horn The new SARS-CoV-2 (COVID-19) virus appeared at the end of December 2019 in Wuhan, China, and soon spread globally. In February 2020, the first cases appeared in Europe, and in…
-
Key Findings from the CAR T-Cell Study Presented at the 2019 AACR Annual Meeting
By Prasad S. Adusumilli, MD, FACS, FCCP Posted: November 12, 2019 My colleagues and I conducted a phase I clinical trial of mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy in patients with malignant pleural disease from mesothelioma and metastatic lung or breast cancer, and we presented the findings at the 2019 American Association for Cancer…
View ILCN Archives
Provider Resources
Popular Articles